☆ 4.5 Letter

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML

BONE MARROW TRANSPLANTATION (2017)

Journal

BONE MARROW TRANSPLANTATION

Volume 52, Issue 4, Pages 620-621

Publisher

NATURE PUBLISHING GROUP

DOI: 10.1038/bmt.2016.326

Keywords

-

Categories

Biophysics Oncology Hematology Immunology Transplantation

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML

Katrin Teich, Michael Stadler, Razif Gabdoulline, Jyoti Kandarp, Clara Wienecke, Bennet Heida, Piroska Klement, Konstantin Buttner, Letizia Venturini, Martin Wichmann, Wolfram Puppe, Christian Schultze-Florey, Christian Koenecke, Gernot Beutel, Matthias Eder, Arnold Ganser, Michael Heuser, Felicitas Thol

Summary: Donor lymphocyte infusions (DLIs) can be used to prevent or treat relapse in acute myeloid leukemia (AML) patients after allogeneic hematopoietic cell transplantation (alloHCT). Measurable residual disease (MRD) is a valuable biomarker for predicting the response and outcome of DLI treatment. This retrospective study showed that MRD status before and after DLI treatment is prognostic for event-free survival, overall survival, cumulative incidence of relapse, and relapse-free survival.

CANCERS (2023)

Add to Collection

Article Hematology

Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients

Boris van der Zouwen, E. A. S. Koster, P. A. von dem Borne, L. E. M. Oosten, M. W. I. Roza-Scholten, T. J. F. Snijders, D. van Lammeren, P. van Balen, W. A. F. Marijt, H. Veelken, J. H. F. Falkenburg, L. C. de Wreede, C. J. M. Halkes

Summary: Prophylactic donor lymphocyte infusion (DLI) can introduce graft-versus-leukemia (GvL) effects with low risk of severe graft-versus-host-disease (GvHD) when initiated at 6 months after T cell-depleted allogeneic stem cell transplantation (TCD-alloSCT). This study retrospectively analyzed the use of low-dose early DLI at 3 months after alloSCT to prevent early relapse.

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Article Oncology

Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

Raynier Devillier, Boris Calmels, Sophie Guia, Mohammed Taha, Cyril Fauriat, Bechara Mfarrej, Geoffroy Venton, Eric Vivier, Daniel Olive, Christian Chabannon, Didier Blaise, Sophie Ugolini

Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective curative option for high-risk hematologic malignancies, but disease recurrence remains a critical issue. NK cell-based immunotherapies offer a promising approach to enhance anti-tumor effects without triggering graft-versus-host disease. This clinical trial demonstrates the safety and potential efficacy of prophylactic donor-derived IL-2 activated NK cell infusion after allo-HSCT for patients with hematologic malignancies.

CANCERS (2021)

Add to Collection

Article Hematology

Pre-emptive and prophylactic donor lymphocyte infusion following allogeneic stem cell transplantation

Kaito Harada

Summary: Donor lymphocyte infusion (DLI) is an allogenic immunotherapy used after allogeneic hematopoietic stem cell transplantation to prevent relapse or as maintenance therapy. DLI takes advantage of the graft-versus-tumor effect but can also lead to graft-versus-host disease. The response and efficacy of DLI depend on various factors, including patient, disease, and DLI factors.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Oncology

Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia

Panagiotis Tsirigotis, Konstantinos Gkirkas, Vassiliki Kitsiou, Spiros Chondropoulos, Theofilos Athanassiades, Thomas Thomopoulos, Alexandra Tsirogianni, Maria Stamouli, Aggeliki Karagiannidi, Nikolaos Siafakas, Vassiliki Pappa, Arnon Nagler

Summary: The study demonstrates that prolonged up to three years of low-dose pro-DLI administered every two months is safe and effective in reducing relapse rate in patients with high-risk acute leukemia. The strategy of low-dose repetitive administration DLI reduces the risk of GVHD and helps in preventing relapse by inducing sustained immunological pressure on residual leukemic cells. Further testing in larger cohorts is warranted to confirm the efficacy of this novel approach in high-risk acute leukemia patients.

CANCERS (2021)

Add to Collection

Article Oncology

Comparison of Two Strategies for Prophylactic Donor Lymphocyte Infusion in Patients With Refractory/Relapsed Acute Leukemia

Qiongqiong Su, Zhiping Fan, Fen Huang, Na Xu, Danian Nie, Dongjun Lin, Ziwen Guo, Pengcheng Shi, Zhixiang Wang, Ling Jiang, Jing Sun, Zujun Jiang, Qifa Liu, Li Xuan

Summary: Delaying prophylactic donor lymphocyte infusion (pDLI) to day +90 based on minimal residual disease (MRD) for patients with refractory/relapsed acute leukemia undergoing allo-HSCT could reduce extensive chronic GVHD incidence and improve GVHD-free/relapse-free survival (GRFS) without increasing the risk of leukemia relapse.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study

Rui Zhang, Lili Wang, Peng Chen, Xiaoning Gao, Shuhong Wang, Fei Li, Liping Dou, Chunji Gao, Yan Li, Daihong Liu

Summary: The study demonstrated the feasibility of prophylactic DLI with/without decitabine in the early stage post-allo-HSCT in patients with unfavourable gene mutations. Significant associations were found between acute GVHD and relapse after DLI with inferior overall survival.

CANCER MEDICINE (2021)

Add to Collection

Article Hematology

Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion

Neal Shah, Kevin Rakszawski, Myles Nickolich, Christopher Ehmann, Baldeep Wirk, Seema Naik, Witold Rybka, Hong Zheng, Joseph Mierski, Brooke Silar, Gina Mackey, Robert Greiner, Valerie Brown, David Claxton, Shin Mineishi, Kentaro Minagawa

Summary: This study evaluated the outcomes of AML relapse after alloSCT and found that H + CT could improve the 1-year overall survival rate of patients, especially for those with a post-alloSCT relapse duration of less than 6 months.

ANNALS OF HEMATOLOGY (2021)

Add to Collection

Article Immunology

Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion

Eva A. S. Koster, Edouard F. Bonneville, Peter A. von dem Borne, Peter van Balen, Erik W. A. Marijt, Jennifer M. L. Tjon, Tjeerd J. F. Snijders, Danielle van Lammeren, Hendrik Veelken, Hein Putter, J. H. Frederik Falkenburg, Constantijn J. M. Halkes, Liesbeth C. de Wreede

Summary: Alloreactive donor-derived T-cells play a crucial role in alloimmune responses after allogeneic hematopoietic stem cell transplantation (alloSCT), affecting both the prevention of leukemia relapse and the risk of graft-versus-host disease (GvHD). This study investigates the complex associations between T-cell kinetics and alloimmune responses in acute leukemia patients receiving alemtuzumab-based T-cell depletion alloSCT. The results demonstrate that donor lymphocyte infusion (DLI) can lead to detectable T-cell expansion, with CD4+ T-cells showing the strongest association with the development of alloimmune responses.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Oncology

Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post-transplant cyclophosphamide for treatment of high-risk myeloid neoplasms in children: A retrospective study

Shan-shan Qi, Zhi Chen, Yu Du, Ming Sun, Zhuo Wang, Fei Long, Linlin Luo, Hao Xiong

Summary: This study retrospectively analyzed the efficacy and safety of PTCy regimen for GvHD prophylaxis and pro-DLI treatment in pediatric patients with high-risk myeloid neoplasms. The results showed that this regimen is effective and safe for treating high-risk myeloid neoplasms in pediatric patients.

PEDIATRIC BLOOD & CANCER (2023)

Add to Collection

Article Oncology

Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion

Tingting Han, Yuqian Sun, Yang Liu, Chenhua Yan, Yu Wang, Lanping Xu, Kaiyan Liu, Xiaojun Huang, Xiaohui Zhang

Summary: This study retrospectively analyzed the efficacy of a second allogeneic hematopoietic stem cell transplantation (HSCT2) in 28 patients with relapsed/refractory acute leukemia after chemotherapy plus modified donor lymphocyte infusion following the first allo-HSCT (HSCT1). The findings showed a high rate of complete remission in patients post-HSCT2, with overall survival (OS) and disease-free survival (DFS) rates at 1 year post-HSCT2 being 25.0% and 21.4%, respectively. Risk factors for OS post-HSCT2 included risk stratification prior to HSCT1 and blast percentage before HSCT2, while relapse within 6 months post-HSCT1 was a risk factor for DFS and relapse post-HSCT2. The study suggests that HSCT2 could be a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion.

FRONTIERS OF MEDICINE (2021)

Add to Collection

Review Oncology

Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering

Yishan Ye, Luxin Yang, Xiaolin Yuan, He Huang, Yi Luo

Summary: Donor lymphocyte infusion (DLI) is a key strategy for treating AML relapse, but the prognosis remains poor. Recent advances in using novel targeted and immunomodulatory agents, as well as manipulation of DLI graft, have shown potential for improving treatment efficacy.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Hematology

Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia

Kaito Harada, Shohei Mizuno, Shingo Yano, Akiyoshi Takami, Hiroto Ishii, Kazuhiro Ikegame, Yuho Najima, Shinichi Kako, Takashi Ashida, Souichi Shiratori, Shuichi Ota, Makoto Onizuka, Kentaro Fukushima, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Masamitsu Yanada

Summary: Although haploidentical donor lymphocyte infusion (DLI) is a valid treatment option for relapsed acute myeloid leukemia (AML), the incidence and risk factors for graft-versus-host disease (GVHD) and the efficacy of haploidentical DLI have not been fully evaluated. Our retrospective analysis showed that a higher CD3(+) cell count was associated with an increased risk of acute GVHD, and preemptive DLI resulted in better overall response.

ANNALS OF HEMATOLOGY (2022)

Add to Collection

Article Hematology

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant

Premal D. Lulla, Swati Naik, Spyridoula Vasileiou, Ifigeneia Tzannou, Ayumi Watanabe, Manik Kuvalekar, Suhasini Lulla, George Carrum, Carlos A. Ramos, Rammurti Kamble, LaQuisa Hill, Jasleen Randhawa, Stephen Gottschalk, Robert Krance, Tao Wang, Mengfen Wu, Catherine Robertson, Adrian P. Gee, Betty Chung, Bambi Grilley, Malcolm K. Brenner, Helen E. Heslop, Juan F. Vera, Ann M. Leen

Summary: Leukemia-specific T cells (mLSTs) selectively recognized and killed leukemia antigen-pulsed cells in vitro, showing no activity against recipient's normal cells. Infusions of mLSTs were well tolerated with no severe GVHD, leading to antileukemia effects and promising outcomes for AML/MDS patients after HCT.

BLOOD (2021)

Add to Collection

Review Oncology

Treatment of AML Relapse After Allo-HCT

Jonathan A. Webster, Leo Luznik, Ivana Gojo

Summary: Advances in allo-HCT have shifted the primary cause of treatment failure for AML patients from transplant-related mortality to disease relapse. Post-transplant relapsed AML presents a clinical challenge due to transplant-related toxicities increasing the risk of treatment-related morbidity and mortality.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Biophysics

Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation

Anne Banet, Ali Bazarbachi, Myriam Labopin, Nicolas Stocker, Remy Dulery, Florent Malard, Zoe Van de Wyngaert, Alexis Genthon, Mara Memoli, Ollivier Legrand, Agnes Bonnin, Tounes Ledraa, Ramdane Belhocine, Simona Sestili, Jean El-Cheikh, Mohamad Mohty, Eolia Brissot

Summary: Total body irradiation (TBI)-based conditioning regimens are commonly used in acute lymphoblastic leukemia (ALL) patients, but studies have shown comparable outcomes with thiotepa-based conditioning regimen. In this retrospective study, we evaluated the outcome of adult ALL patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HCT) with a thiotepa-busulfan-fludarabine (TBF) myeloablative conditioning regimen. The results showed promising overall survival and acceptable toxicity in these patients.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Biophysics

Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study

Mohamad Mohty, Didier Blaise, Regis Peffault de Latour, Myriam Labopin, Jean Henri Bourhis, Benedicte Bruno, Patrice Ceballos, Marie Detrait, Virginie Gandemer, Anne Huynh, Faezeh Izadifar-Legrand, Charlotte Jubert, Helene Labussiere-Wallet, Delphine Lebon, Sebastien Maury, Catherine Paillard, Cecile Pochon, Cecile Renard, Fanny Rialland, Pascale Schneider, Anne Sirvent, Kobby Asubonteng, Gwennaelle Guindeuil, Ibrahim Yakoub-Agha, Jean-Hugues Dalle

Summary: This study evaluated the effectiveness and safety of defibrotide in patients undergoing haematopoietic cell transplantation (HCT). The results showed that defibrotide had a good effect in treating severe/very severe VOD/SOS, with high survival and complete response rates.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Biophysics

Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies

Remy Dulery, Claire Goudet, Daniele Mannina, Antonio Bianchessi, Angela Granata, Samia Harbi, Valerio Maisano, Christian Chabannon, Florent Malard, Eolia Brissot, Simona Sestili, Anne Banet, Zoe van de Wyngaert, Ramdane Belhocine, Stephane Ederhy, Luca Castagna, Stefania Bramanti, Didier Blaise, Mohamad Mohty, Sabine Fuerst, Raynier Devillier

Summary: Comparing the outcomes of PT-Cy at 80 mg/kg and 100 mg/kg in elderly patients undergoing haploidentical HCT, it was found that reducing the PT-Cy dose to 80 mg/kg improved hematological recovery and reduced the incidence of hemorrhagic cystitis.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Biophysics

Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study

Jean El Cheikh, Ghassan Bidaoui, Ali Atoui, Khodr Terro, Layal Sharrouf, Ammar Zahreddine, Nour Moukalled, Imane Abou Dalle, Ali Bazarbachi, Mohamad Mohty, Remy Dulery

Summary: This study evaluates the outcome of high-risk hematological malignancies patients who received Clo/TBI (4-8 Gy) as a conditioning regimen before allo-SCT. It shows that Clo/TBI is effective in disease control with an acceptable toxicity profile for high-risk patients.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Oncology

Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT

Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermudez Rodriguez, Peter Remenyi, Christoph Schmid, Eolia Brissot, Jaime Sanz, Ali Bazarbachi, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty

Summary: Comparing outcomes of adult patients with secondary acute myeloid leukemia (sAML) and de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide, no significant difference was observed in transplantation outcomes between the two groups.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

ALLO HSCT IN OLDER PATIENTS: A QUESTION OF REAL PERSONALIZED MEDICINE

D. Blaise

LEUKEMIA RESEARCH (2023)

Add to Collection

Article Cell Biology

Prognostic Immune Effector Signature in Adult Acute Lymphoblastic Leukemia Patients Is Dominated by ?d T Cells

Anne-Charlotte Le Floch, Marie-Sarah Rouviere, Nassim Salem, Amira Ben Amara, Florence Orlanducci, Norbert Vey, Laurent Gorvel, Anne-Sophie Chretien, Daniel Olive

Summary: This study explored the impact of circulating ?d T-cell alterations on prognosis in newly diagnosed adult ALL patients. They found common alterations in CD8(+) T cells and ?d T cells of relapsed patients, including accumulation of early stage differentiation and increased expression of BTLA and CD73. The circulating ?d T-cell signature and Vd2 T-cell alterations were found to strongly discriminate patients by relapse status. These findings suggest the importance of Gd T cells, especially Vd2 T cells, in T-cell immunity and provide a rationale for further monitoring and enhancing Vd2 T cells in ALL.

CELLS (2023)

Add to Collection

Article Multidisciplinary Sciences

Niche-expressed Galectin-1 is involved in pre-B acute lymphoblastic leukemia relapse through pre-B cell receptor activation

Jeoffrey Pelletier, Marielle Balzano, Jerome Destin, Camille Montersino, Marjorie C. Delahaye, Tony Marchand, Anne-Laure Bailly, Florence Bardin, Emilie Coppin, Armelle Goubard, Remy Castellano, Marjolein J. W. de Bruijn, Jasper Rip, Yves Collette, Patrice Dubreuil, Karin Tarte, Cyril Broccardo, Rudi W. Hendriks, Claudine Schiff, Norbert Vey, Michel Aurrand-Lions, Stephane J. C. Mancini

Summary: B-cell acute lymphoblastic leukemia (B-ALL) is the malignant counterpart of developing B cells in the bone marrow (BM). Galectin-1 (GAL1) expressed in BM niches provides proliferation signals to normal pre-B cells through interaction with the pre-B cell receptor (pre-BCR). In murine and patient-derived xenograft (PDX) models, GAL1 produced by BM niches influences the development of pre-B ALL through pre-BCR-dependent signals, similar to normal pre-B cells. Targeting pre-BCR signaling in combination with cell-autonomous oncogenic pathways improves the treatment response in pre-B ALL PDX. Therefore, non-cell autonomous signals transmitted by BM niches could be potential targets to enhance B-ALL patient survival.

ISCIENCE (2023)

Add to Collection

Article Biophysics

Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome

Samia Harbi, Louison Brac de la Perriere, Benjamin Bouchacourt, Sylvain Garciaz, Thomas Pagliardini, Boris Calmels, Maud Cecile, Anne-Charlotte Lefloch, Yosr Hicheri, Marie-Anne Hospital, Sabine Furst, Claude Lemarie, Cecile Braticevic, Faezeh Legrand, Elena Bekrieva, Pierre-Jean Weiller, Christian Chabannon, Norbert Vey, Didier Blaise, Raynier Devillier

Summary: This article reports the experience of peripheral blood Haplo-SCT in AML and MDS patients aged 70 years and over. The results show that this treatment method is feasible and provides long-term disease control and survival in this age group.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Letter Biophysics

Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT

Lars Klingen Gjaerde, Christophe Peczynski, Emmanuelle Polge, Nicolaus Kroeger, Regis Peffault de Latour, Juergen Finke, Ernst Holler, Didier Blaise, Grzegorz Helbig, Urpu Salmenniemi, Victoria Potter, Donald Bunjes, Lazar Erzsebet, Olaf Penack, Helene Schoemans, Christian Koenecke, Grzegorz W. Basak, Zinaida Peric

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Biophysics

GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation

Francois Dachy, Sabine Furst, Boris Calmels, Thomas Pagliardini, Samia Harbi, Benjamin Bouchacourt, Anne Calleja, Claude Lemarie, Aude Collignon, Guillaume Morel, Faezeh Legrand, Elena Bekrieva, Angela Granata, Pierre Jean Weiller, Christian Chabannon, Jean Marc Schiano, Norbert Vey, Didier Blaise, Raynier Devillier

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Oncology

Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Sebastian Giebel, Myriam Labopin, Urpu Salmenniemi, Gerard Socie, Sergey Bondarenko, Didier Blaise, Nicolaus Kroeger, Jan Vydra, Anna Grassi, Francesca Bonifazi, Tomasz Czerw, Achilles Anagnostopoulos, Bruno Lioure, Annalisa Ruggeri, Bipin Savani, Alexandros Spyridonidis, Jaime Sanz, Zinaida Peric, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Summary: This study compared the efficacy of using rabbit antithymocyte globulin (ATG) and posttransplant cyclophosphamide (PTCY) as immunosuppressive strategies for prophylaxis of graft-versus-host disease (GVHD) in acute lymphoblastic leukemia (ALL) patients. The study found that while the PTCY group had a reduced risk of chronic GVHD, it also had inferior leukemia-free survival compared to the ATG group.

CANCER (2023)

Add to Collection

Editorial Material Mycology

Disseminated Scedosporium Invasive Fungal Infection in Critically ill Newly Diagnosed Acute Myeloid Leukemia Patient Complicated with Cerebritis

Colombe Saillard, Magali Bisbal, Morgan Avenin, Pierre Lehmann, Antoine Sannini, Laurent Chow-Chine, Luca Servan, Frederic Gonzalez, Evelyne d'Incan, Norbert Vey, Djamel Mokart

MYCOPATHOLOGIA (2023)

Add to Collection

Meeting Abstract Oncology

A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies

Courtney D. DiNardo, Pau Montesinos, Lina Benajiba, Ana Triguero, Christian Recher, Andre C. Schuh, Mael Heiblig, Ashish Bajel, Arnaud Pigneux, Juan M. Alonso-Domiguez, Amir T. Fathi, Carolyn Grove, Hsin-An Hou, Michael Heuser, Sarit Assouline, Shaun Fleming, Dong-Yeop Shin, Kendra Sweet, Olatoyosi Odenike, Jessica Altman, Melissa Gaik Ming Ooi, Lao Zhentang, Nobert Vey, Joshua Zeidner, Amandeep Salhotra, Eunice Wang, Gary Schiller, Kimmo Porkka, Tsila Zuckerman, Violaine Havelange, Brian A. Jonas, Sujaatha Narayanan, Jun Ho Jang, Je-Hwan Lee, Anna M. Szpurka, Dana Heirich, Hsiao Rong Chen, Violet Hanft, Junjie Zhao, Ivelina Gueorguieva, Yin Zhang, Eytan M. Stein

CANCER RESEARCH (2023)

Add to Collection

Article Hematology

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma

Robin Noel, Christophe Zemmour, Catalina Montes de Oca, Nawel Belmecheri, Therese Aurran-Schleinitz, Diane Coso, Leonor Lopez Almeida, Lenaig Mescam, Norbert Vey, Jean Sebastien Blade, Borhane Slama, Reda Bouabdallah, Jean-Marc Schiano de Colella

Summary: This prospective phase 2 study aimed to evaluate the efficacy of Rituximab and Lenalidomide (R2) in Relapsed/Refractory Diffuse Large B Cell Lymphoma patients. However, the study failed to achieve its primary endpoint, indicating that R2 regimen is not recommended for patients with high-risk features.

HEMATOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.